Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers

NCT02238782 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02238782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02238782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
November 30, 2014
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers bioavailability study